DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that KBI BioPharma, Inc., has completed and validated a second analytical method for PT-401, based on SDS-PAGE, a well established separation technique that will be used for in-process analysis, release and stability testing for its PT-401 anemia drug, which is being developed by its subsidiary, DNAPrint Pharmaceuticals, Inc.
